286 related articles for article (PubMed ID: 29098904)
21. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.
Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM
Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719
[TBL] [Abstract][Full Text] [Related]
22. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
[TBL] [Abstract][Full Text] [Related]
23. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
27. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
Soliman AM; Alqahtani AS; Ghorab M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y
Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Anti-Proliferation Activity Evaluation of Novel 2-Chloroquinazoline as Potential EGFR-TK Inhibitors.
Zheng Q; Xu XB; Jin H; Zhang W; Rao GW
Chem Biodivers; 2021 Nov; 18(11):e2100478. PubMed ID: 34510749
[TBL] [Abstract][Full Text] [Related]
31. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment.
Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838
[TBL] [Abstract][Full Text] [Related]
33. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Zhang Y; Chen L; Xu H; Li X; Zhao L; Wang W; Li B; Zhang X
Eur J Med Chem; 2018 Mar; 147():77-89. PubMed ID: 29421573
[TBL] [Abstract][Full Text] [Related]
34. Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
Wang Z; Wu X; Wang L; Zhang J; Liu J; Song Z; Tang Z
Bioorg Med Chem Lett; 2016 Jun; 26(11):2589-93. PubMed ID: 27118497
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors.
Abdelgawad MA; Bakr RB; Alkhoja OA; Mohamed WR
Bioorg Chem; 2016 Jun; 66():88-96. PubMed ID: 27043178
[TBL] [Abstract][Full Text] [Related]
36. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
37. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
[TBL] [Abstract][Full Text] [Related]
39. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
Ahmed MF; Magdy N
Anticancer Agents Med Chem; 2017; 17(6):832-838. PubMed ID: 27671305
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
